Here are the latest publicly reported updates on Novo Nordisk.
-
Company-wide news and press releases
- Novo Nordisk’s official newsroom provides up-to-date press releases, business milestones, and strategic updates. You can check there for the most authoritative statements and dates [Novo Nordisk Newsroom].
- The company’s U.S. media hub also aggregates recent news releases and sign-up options for alerts [Novo Nordisk U.S. News & Media Hub].
-
Market and regulatory context (recent highlights)
- There have been ongoing discussions about Wegovy and Ozempic pricing, access programs, and legal actions related to knock-off semaglutide products in various markets [industry news aggregators and major outlets].
- In late 2024 and 2025, there were reports of price adjustments and accessibility programs aimed at broadening patient access, including partnerships and promotional pricing in some regions [news aggregators and financial press].
-
Financial and clinical updates (selection)
- Novo Nordisk’s quarterly results have shown continued strength in diabetes and obesity franchises, even as the company navigates pricing pressures and competition. Investors often focus on revenue growth, margin stability, and pipeline progress [major business press and financial coverage].
- The company’s clinical program updates, including obesity and diabetes therapies, are regularly summarized in press releases and clinical trial news columns, with emphasis on efficacy signals, safety, and regulatory status [company announcements and trial news].
Illustration of where to look first
- Start at the official Newsroom and U.S. Media Hub for primary, citable statements:
If you’d like, I can monitor for new articles and summarize them with timestamped headlines and key takeaways. I can also pull a quick side-by-side of recent Wegovy pricing updates by region if you specify your preferred markets.
Citations:
- Novo Nordisk Newsroom and U.S. News & Media Hub provide official updates and press releases [Novo Nordisk Newsroom, Novo Nordisk U.S. News & Media Hub].
- Major business and health-news outlets regularly report on pricing, access programs, and trial results affecting Novo Nordisk [general industry coverage].
Sources
A one-month supply of Ozempic and Wegovy will now cost $499 out of pocket for Costco shoppers. Novo Nordisk said the job cuts will eliminate about 11% of its workforce, with 5,000 of the reductions in Denmark. The maker of Ozempic is cutting the price of the drug nearly in half for some patients. Novo Nordisk had already cut the price of Wegovy, a medication with the same active ingredient that's approved for weight loss. Dr. Celine Gounder has more on the emerging price competition over the...
www.cbsnews.comWelcome to Novo Nordisk's U.S. news and media hub. Here you can access our news releases, social media accounts, media contacts, sign up for email alerts, and more.
www.novonordisk-us.comnews
www.prnewswire.comFind archived news and media from Novo Nordisk U.S.
www.novonordisk-us.comFollow Novo Nordisk A/S (NVO) news, including Wegovy approvals, GLP‑1 obesity and MASH updates, pricing programs, pipeline data, and key corporate announcements.
www.stocktitan.netdanish drug maker novo nordisk Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. danish drug maker novo nordisk Blogs, Comments and Archive News on Economictimes.com
economictimes.indiatimes.comNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
www.novonordisk.comHere journalists can access a concise and up-to-date overview of our company’s key facts, figures, and milestones.
www.novonordisk.com